StockNews.AI
ORGO
StockNews.AI
204 days

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

1. Organogenesis will report Q4 and FY 2024 results on February 27. 2. Management will host a conference call at 5:00 p.m. ET on the reporting date. 3. The company focuses on regenerative medicine for wound care and sports medicine. 4. Past financial results have influenced stock performance and investor sentiment. 5. Future announcements may impact ORGO's market perception and stock price.

3m saved
Insight
Article

FAQ

Why Neutral?

While earnings reports can influence price, expectations are uncertain. Similar past reports have led to mixed market reactions.

How important is it?

The upcoming earnings report directly relates to ORGO's financial health and future growth. Market anticipation can moderate its impact depending on reported figures.

Why Short Term?

Immediate reactions may occur post-report, with potential long-term effects depending on results. Previous earnings releases often show short-term volatility.

Related Companies

ORGO
CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market closes on Thursday, February 27th. Management will host a conference call at 5:00 p.m. Eastern Time on February 27th to discuss the results of the quarter and fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year. About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

Related News